Used in the treatment of inflammatory diseases, particularly asthma and atopic dermatitis, by targeting and neutralizing thymic stromal lymphopoietin (TSLP), a key cytokine involved in initiating and amplifying allergic inflammatory responses. This antibody helps reduce airway inflammation, decrease exacerbation rates, and improve lung function in asthma patients. It is also being investigated for chronic rhinosinusitis, eosinophilic esophagitis, and other type 2 inflammatory conditions. Due to its upstream targeting of immune activation, it may provide broad inhibition of multiple inflammatory pathways, offering potential benefits in patients unresponsive to other biologic therapies.